Banyan Biomarkers, Inc.

University of Florida Research Foundation, Incorporated

US Government As Represented by the Secretary of the Army

The State University of New York

Bioregency, Inc.

Kevin Ka-Wang Wang

Monika Oli

Ronald L Hayes

Ming-Cheng Liu

Zhiqun Zhang

Stanislav Igorevich Svetlov

Ming Chen Liu

Alvin Wang

Gabriel Molina

Victor Prima

Richard Rubenstein

Jitendra Ramanlal Dave

Zhihui Yang

Ahmed Moghieb

Uwe R Muller

Uwe R Mueller

Ming Cheng Liu

Uwe R Müller

Jitendra Dave

The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.

Biomarker detection process and assay of neurological condition

The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Neural proteins as biomarkers for nervous system injury and other neural disorders

Proteins that are differentially expressed or elevated in tissue and biofluids after central nervous system injuries are described. Elevated or reduced levels of the proteins, alone or in various combinations or ratios, can be used to assess severity of central nervous system injury (CNS injury) including traumatic brain injury (TBI), traumatic spinal cord injury (SCI) and chronic traumatic encephalopathy (CTE). Time course measurements post CNS-injury of these proteins can be used to monitor progress or recovery over periods up to several months. Differentiation of acute, subacute and chronic injury can be diagnosed by comparing the protein levels in CNS-injury patients at days 1-3, day 4-10 with levels at day 30-180 in comparison with normal controls.

Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system

Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby argininosuccinate synthetase or PEGylated argininosuccinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.

Compositions and methods relating to argininosuccinate synthetase

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury

Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby arginino succinate synthetase or PEGylated arginino succinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.

Compositions and methods relating to argininosucccinate synthetase

The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Proteolytic biomarkers for traumatic injury to the nervous system

Neural proteins as biomarkers for traumatic brain injury

Growing community of inventors

Gainesville, FL, United States of America

Kevin Ka-Wang Wang